Can HE4 predict platinum response during first-line chemotherapy in ovarian cancer?

Tumor Biology

Volumn 35, Issue 7, 2014, Pages 7009-7015

  Angioli, Roberto ^a   Capriglione, Stella ^a   Aloisi, Alessia ^a   Guzzo, Federica ^a   Luvero, Daniela ^a   Miranda, Andrea ^a   Damiani, Patrizio ^a   Montera, Roberto ^a   Terranova, Corrado ^a   Plotti, Francesco ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

CA125; Chemoresponse; HE4; Ovarian cancer; Platinum resistant; Platinum sensitive

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; HUMAN EPIDIDYMIS PROTEIN 4; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

ADULT; AGED; BIOMARKERS, PHARMACOLOGICAL; CA-125 ANTIGEN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PLATINUM; PROGNOSIS; PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84904973595     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1836-x     Document Type: Article

References (20)

1. Berek JS, Crum C. Friedlander M Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2012;119 Suppl 2:S118-29.
2. Markman M. Optimizing primary chemotherapy in ovarian cancer. Hematol Oncol Clin North Am. 2003;17:957-68. (Pubitemid 37022151)
3. Markman M, Federico M, Liu PY, et al. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer. Gynecol Oncol. 2006;103:195-8. (Pubitemid 44389869)
4. Tuxen MK, Soletormos G, Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev. 1995;21:215-45.
5. Cooper BC, Sood AK, Davis CS, Ritchie JM, Sorosky JI, Anderson B, et al. Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol. 2002;100:59-64. (Pubitemid 34722843)
6. Rustin GJS, Gennings JN, Nelstrop AE, Covarrubias H, Lambert HE, Bagshawe KD. Use of CA-125 to predict survival of patients with ovarian carcinoma. J Clin Oncol. 1989;7:1667-71. (Pubitemid 19272837)
7. Koper NP, Massuger LFAG, Thomas CMG, Kiemeney LALM, Schijf CPT, Beex LVAM, et al. Prognostic value of serial CA 125 measurements during chemotherapy for patients with advanced ovarian cancer. Int J Gynecol Cancer. 1997;7:127-33. (Pubitemid 27237400)
8. Mogensen O. Prognostic value of CA 125 in advanced ovarian cancer. Gynecol Oncol. 1992;44:207-12.
9. Latimer JA, Beng CG, Davy MLJ. For stage III epithelial ovarian cancer the initial level of expression of CA 125 does not correlate with survival in women who respond to treatment. Int J Gynecol Cancer. 1996;6:380-4. (Pubitemid 26268899)
10. Peters-Engl C, Obermair A, Heinzl H, Buxbaum P, Sevelda P, Medl M. CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer. Br J Cancer. 1999;81:662-6. (Pubitemid 29458862)
11. Frasci G, Conforti S, Zullo F, Mastrantonio P, Comella G, Comella P, et al. A risk model for ovarian carcinoma patients using CA 125. Cancer. 1996;77:1122-30.
12. Rocconi RP, Matthews KS, Kemper MK, et al. The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer. Gynecol Oncol. 2009;114:242-5.
13. World Health Organization. WHO handbook for reporting results of cancer treatment (offset publication no. 48). Geneva: World Health Organization; 1979. p. 16-21.
14. van Dalen A, Favier J, Burges A, Hasholzner U, de Bruijn HWA, Dobler-Girdziunaiti D, et al. Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecol Oncol. 2000;79:444-50.
15. Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108:402-8. (Pubitemid 351174295)
16. Plotti F, Capriglione S, Terranova C, Montera R, Aloisi A, Damiani P, et al. Does HE4 have a role as biomarker in the recurrence of ovarian cancer? Tumour Biol. 2012;33(6):2117-23.
17. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47.
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16.
19. Hynninen J, Auranen A, Dean K, Lavonius M, Carpen O, Perheentupa A, et al. Serum HE4 profile during primary chemotherapy of epithelial ovarian cancer. Int J Gynecol Cancer. 2011;21(9):1573-8.
20. Steffensen KD, Waldstrøm M, Brandslund I, Jakobsen A. Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients. Int J Gynecol Cancer. 2011;21(6):1040-7.